Market Report

Alzheimer’s Therapeutics Market Report 2026-2036

The global Alzheimer’s Therapeutics market is projected to grow at a CAGR of 18.2% by 2036

SKU: PHA1381 Category: Code: PHA1381Pages: 269
Clear
← Back to category Therapeutic Drugs

Description

The Alzheimer’s Therapeutics Market Report 2026-2036 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Global Burden of Alzheimer’s Disease Continues to Drive Market Demand

The persistent rise in global Alzheimer’s disease prevalence continues to anchor long‑term demand for therapeutics and sustained healthcare investment. Real‑world evidence presented by Eisai and Biogen at AAIC 2025 showed that two years of continuous lecanemab (LEQEMBI®) treatment resulted in high rates of therapy continuation and relatively low discontinuation due to adverse events, reinforcing that real‑world uptake remains strong despite clinical and logistical challenges. Commercially, this supports longer treatment durations per patient and strengthens lifetime‑value models that increasingly favour disease‑modifying therapies over short‑course symptomatic care. The therapy’s availability in more than 45 countries further amplifies this trend, prompting healthcare systems to plan for extended treatment regimens and encouraging payers to adopt long‑horizon cost‑effectiveness frameworks that account for earlier intervention and prolonged disease management.

What would be the Impact of US Trade Tariffs on the Global Alzheimer’s Therapeutics Market?

U.S. trade tariffs would reshape the global Alzheimer’s therapeutics market primarily by increasing upstream manufacturing and cross‑border supply‑chain costs rather than directly constraining finished‑drug availability. Disease‑modifying therapies—especially monoclonal antibodies—depend on globally distributed production networks spanning biologics drug‑substance manufacturing, fill‑finish operations, delivery‑device assembly, specialised packaging, and cold‑chain logistics. Much of this infrastructure sits in Europe and Asia, making the category highly sensitive to tariff‑driven cost inflation.

Higher landed costs in the U.S. would intensify payer scrutiny, slow reimbursement negotiations, and reinforce narrower patient‑eligibility criteria for premium DMTs. For manufacturers, tariffs would compress margins and accelerate strategic shifts toward U.S.‑based production, fill‑finish localisation, and deeper reliance on domestic CDMOs—moves that raise capital intensity in the short term but reduce geopolitical exposure over time.

Globally, these pressures could delay launch sequencing in secondary markets, divert investment away from smaller innovators with limited pricing flexibility, and widen access disparities between the U.S. and cost‑sensitive regions. Rather than triggering a demand shock, tariffs would function as a structural cost and access headwind, reshaping competitive strategy, manufacturing footprints, and payer behaviour across the Alzheimer’s therapeutics landscape.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the Alzheimer’s Therapeutics market evolving?
  • What is driving and restraining the Alzheimer’s Therapeutics market?
  • How will each Alzheimer’s Therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
  • How will the market shares for each Alzheimer’s Therapeutics submarket develop from 2026 to 2036?
  • What will be the main driver for the overall market from 2026 to 2036?
  • Will leading Alzheimer’s Therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2036 and which geographical region will lead the market in 2036?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Alzheimer’s Therapeutics projects for these leading companies?
  • How will the industry evolve during the period between 2026 and 2036? What are the implications of
    Alzheimer’s Therapeutics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Alzheimer’s Therapeutics market?
  • Where is the Alzheimer’s Therapeutics market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Alzheimer’s Therapeutics market today, and over the next 10 years:

  • Our 269-page report provides 102 tables and 176 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2036 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2036, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

Drug Class

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Combination Drugs
  • Others

Type of Treatment

  • Symptomatic
  • Disease-Modifying Therapies (DMTs)

Route of Administration

  • Oral
  • Injectable
  • Transdermal

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 19 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Alzheimer's Therapeutics Market Report 2026-2036
Need industry data? Please contact us today.

The report also includes profiles for some of the leading companies in the Alzheimer’s Therapeutics Market, 2026 to 2036, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

  • AbbVie Inc.
  • AC IMMUNE SA
  • Biogen
  • Eisai Inc.
  • GSK plc
  • Grifols, S.A.
  • Janssen Pharmaceutica NV
  • Neurim Pharmaceuticals LTD.
  • Novo Nordisk
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Merck & Co., Inc.

Overall world revenue for Alzheimer’s Therapeutics Market, 2026 to 2036 in terms of value the market will surpass US$6.0 billion in 2026, our work calculates. We predict strong revenue growth through to 2036. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Alzheimer’s Therapeutics Market, 2026 to 2036 report help you?

In summary, our 290+ page report provides you with the following knowledge:

  • Revenue forecasts to 2036 for Alzheimer’s Therapeutics Market 2026 to 2036, with forecasts for Drug Class, Type of Treatment, Route of Administration, Distribution Channel, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2036 for five regional and 19 key national markets – See forecasts for the Alzheimer’s Therapeutics Market, 2026 to 2036 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 14 of the major companies involved in the Alzheimer’s Therapeutics Market, 2026 to 2036.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Alzheimer’s Therapeutics Market 2026 to 2036, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Alzheimer’s Therapeutics Market Report 2026-2036 (Including Impact of U.S. Trade Tariffs): Forecasts by Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Combination Drugs, Others), by Type of Treatment (Symptomatic, Disease-Modifying Therapies (DMTs)), by Route of Administration (Oral, Injectable, Transdermal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Alzheimer’s Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Increasing Occurrence of Alzheimer’s Disease to Drive Industry Growth
3.3.1.2 Large Number of Undiagnosed Patient’s and Revised Diagnostic Guidelines to Propel Market Growth
3.3.1.3 Growing Awareness and Improving Diagnosis Rate
3.3.2 Market Restraining Factors
3.3.2.1 Shortage of Skilled Medical Professionals
3.3.2.2 Lack of Proper Treatment Techniques
3.3.3 Market Opportunities
3.3.3.1 Surge in Merger & Acquisitions
3.3.3.2 Increasing R&D Investments
3.4 U.S. Tariffs: What’s the Impact on Global Alzheimer’s Therapeutics Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.3 Why V-Shaped Recovery?
3.4.3.1 Impact from Tariffs
3.4.3.2 Market Dynamics and Demand Recovery
3.4.3.3 Policy and Funding Support
3.4.3.4 Timeframe for Recovery
3.4.4 U-Shaped Recovery Scenario
3.4.4.1 Why U-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 L Shaped Recovery Scenario
3.4.5.1 Why L-Shaped Recovery?
3.4.5.2 Impact from Tariffs
3.4.5.3 Market Dynamics and Demand Recovery
3.4.5.4 Policy and Funding Support
3.4.5.5 Timeframe for Recovery
3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026–2031) and Long-term (2026–2036) Planning?
3.4.7 Impact of U.S. and China Trade War on Alzheimer’s Therapeutics Market
3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Suppliers
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 Alzheimer’s Therapeutics Market Analysis by Drug Class
4.1 Key Findings
4.2 Drug Class Segment: Market Attractiveness Index
4.3 Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
4.4 Cholinesterase Inhibitors
4.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.5 NMDA Receptor Antagonists
4.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.5.2 Market Share by Region, 2026 & 2036 (%)
4.6 Combination Drugs
4.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.6.2 Market Share by Region, 2026 & 2036 (%)
4.7 Others
4.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.7.2 Market Share by Region, 2026 & 2036 (%)

5 Alzheimer’s Therapeutics Market Analysis by Type of Treatment
5.1 Key Findings
5.2 Type of Treatment Segment: Market Attractiveness Index
5.3 Alzheimer’s Therapeutics Market Size Estimation and Forecast by Type of Treatment
5.4 Symptomatic
5.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Disease-Modifying Therapies (DMTs)
5.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.5.2 Market Share by Region, 2026 & 2036 (%)

6 Alzheimer’s Therapeutics Market Analysis by Route of Administration
6.1 Key Findings
6.2 Route of Administration Segment: Market Attractiveness Index
6.3 Alzheimer’s Therapeutics Market Size Estimation and Forecast by Route of Administration
6.4 Oral
6.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.5 Injectable
6.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.5.2 Market Share by Region, 2026 & 2036 (%)
6.6 Transdermal
6.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.6.2 Market Share by Region, 2026 & 2036 (%)

7 Alzheimer’s Therapeutics Market Analysis by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital Pharmacies
7.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 Retail Pharmacies
7.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 Online Pharmacies
7.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.6.2 Market Share by Region, 2026 & 2036 (%)

8 Alzheimer’s Therapeutics Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Alzheimer’s Therapeutics Market Analysis
9.1 Key Finding
9.2 North America Alzheimer’s Therapeutics Market Attractiveness Index
9.3 North America Alzheimer’s Therapeutics Market by Country, 2026, 2031 & 2036 (US$ Billion)
9.4 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
9.5 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
9.6 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Type of Treatment
9.7 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Route of Administration
9.8 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
9.9 U.S. Alzheimer’s Therapeutics Market Analysis
9.10 Canada Alzheimer’s Therapeutics Market Analysis

10 Europe Alzheimer’s Therapeutics Market Analysis
10.1 Key Findings
10.2 Europe Alzheimer’s Therapeutics Market Attractiveness Index
10.3 Europe Alzheimer’s Therapeutics Market by Country, 2026, 2031 & 2036 (US$ Billion)
10.4 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
10.5 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
10.6 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Type of Treatment
10.7 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Route of Administration
10.8 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
10.9 Germany Alzheimer’s Therapeutics Market Analysis
10.10 UK Alzheimer’s Therapeutics Market Analysis
10.11 France Alzheimer’s Therapeutics Market Analysis
10.12 Italy Alzheimer’s Therapeutics Market Analysis
10.13 Spain Alzheimer’s Therapeutics Market Analysis
10.14 Rest of Europe Alzheimer’s Therapeutics Market Analysis

11 Asia Pacific Alzheimer’s Therapeutics Market Analysis
11.1 Key Findings
11.2 Asia Pacific Alzheimer’s Therapeutics Market Attractiveness Index
11.3 Asia Pacific Alzheimer’s Therapeutics Market by Country, 2026, 2031 & 2036 (US$ Billion)
11.4 Asia Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
11.5 Asia Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
11.6 Asia Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Type of Treatment
11.7 Asia Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Route of Administration
11.8 Asia Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
11.9 Japan Alzheimer’s Therapeutics Market Analysis
11.10 China Alzheimer’s Therapeutics Market Analysis
11.11 India Alzheimer’s Therapeutics Market Analysis
11.12 Australia Alzheimer’s Therapeutics Market Analysis
11.13 Rest of Asia Pacific Alzheimer’s Therapeutics Market Analysis

12 Latin America Alzheimer’s Therapeutics Market Analysis
12.1 Key Findings
12.2 Latin America Alzheimer’s Therapeutics Market Attractiveness Index
12.3 Latin America Alzheimer’s Therapeutics Market by Country, 2026, 2031 & 2036 (US$ Billion)
12.4 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
12.5 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
12.6 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Type of Treatment
12.7 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Route of Administration
12.8 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
12.9 Brazil Alzheimer’s Therapeutics Market Analysis
12.10 Mexico Alzheimer’s Therapeutics Market Analysis
12.11 Rest of Latin America Alzheimer’s Therapeutics Market Analysis

13 MEA Alzheimer’s Therapeutics Market Analysis
13.1 Key Findings
13.2 MEA Alzheimer’s Therapeutics Market Attractiveness Index
13.3 MEA Alzheimer’s Therapeutics Market by Country, 2026, 2031 & 2036 (US$ Billion)
13.4 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
13.5 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
13.6 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Type of Treatment
13.7 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Route of Administration
13.8 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
13.9 GCC Alzheimer’s Therapeutics Market Analysis
13.10 South Africa Alzheimer’s Therapeutics Market Analysis
13.11 Rest of MEA Alzheimer’s Therapeutics Market Analysis

14 Company Profiles
14.1 AbbVie Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.3.1 Net Revenue, 2020-2024
14.1.3.2 R&D, 2020-2024
14.1.3.3 Regional Market Shares, 2024
14.1.3.4 Business Segment Market Shares, 2024
14.1.4 Product Benchmarking
14.1.5 Strategic Outlook
14.2 AC IMMUNE SA
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2022-2024
14.2.3.2 R&D, 2020-2024
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 Biogen
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2020-2024
14.3.3.2 R&D, 2020-2024
14.3.3.3 Regional Market Shares, 2024
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Eisai Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2020-2024
14.4.3.2 R&D, 2020-2024
14.4.3.3 Regional Market Shares, 2024
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 GSK plc
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2020-2024
14.5.3.2 R&D, 2020-2024
14.5.3.3 Regional Market Shares, 2024
14.5.3.4 Business Segment Market Shares, 2024
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Grifols, S.A.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2020-2024
14.6.3.2 R&D, 2020-2024
14.6.3.3 Regional Market Shares, 2024
14.6.3.4 Business Segment Market Shares, 2024
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Janssen Pharmaceutica NV
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2020-2024
14.7.3.2 R&D, 2020-2024
14.7.3.3 Regional Market Shares, 2024
14.7.3.4 Business Segment Market Shares, 2024
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Neurim Pharmaceuticals LTD.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.9 Novo Nordisk
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2020-2024
14.9.3.2 R&D, 2020-2024
14.9.3.3 Regional Market Shares, 2024
14.9.3.4 Business Segment Market Shares, 2024
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 F. Hoffmann-La Roche Ltd
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2020-2024
14.10.3.2 R&D, 2020-2024
14.10.3.3 Business Segment Market Shares, 2024
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 Takeda Pharmaceutical Company Limited
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2020-2024
14.11.3.2 R&D, 2020-2024
14.11.3.3 Regional Market Shares, 2024
14.11.4 Product Benchmarking
14.12 Eli Lilly and Company
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2020-2024
14.12.3.2 R&D, 2020-2024
14.12.3.3 Regional Market Shares, 2024
14.12.3.4 Business Segment Market Shares, 2024
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Merck & Co., Inc.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2020-2024
14.13.3.2 R&D, 2020-2024
14.13.3.3 Regional Market Shares, 2024
14.13.3.4 Business Segment Market Shares, 2024
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook

15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players

List of Tables
Table 1 Alzheimer’s Therapeutics Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Alzheimer’s Therapeutics Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Alzheimer’s Therapeutics Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Alzheimer’s Therapeutics Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 5 Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 6 Cholinesterase Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 NMDA Receptor Antagonists Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 8 Combination Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 9 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 10 Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 11 Symptomatic Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 12 Disease-Modifying Therapies (DMTs) Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 13 Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 14 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 15 Injectable Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 16 Transdermal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 17 Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 18 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 19 Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 20 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 21 Alzheimer’s Therapeutics Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 22 North America Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 23 North America Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 24 North America Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 25 North America Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 26 North America Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 27 U.S. Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 28 Canada Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 29 Europe Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 Europe Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 31 Europe Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 32 Europe Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 33 Europe Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 34 Germany Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 35 UK Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 36 France Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 37 Italy Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 38 Spain Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 39 Rest of Europe Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 40 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 41 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 42 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 43 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 44 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 45 Japan Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 46 China Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 47 India Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 48 Australia Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 49 Rest of Asia Pacific Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 50 Latin America Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 51 Latin America Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Latin America Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 53 Latin America Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 54 Latin America Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 55 Brazil Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 56 Mexico Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 57 Rest of Latin America Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 58 MEA Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 59 MEA Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 60 MEA Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 61 MEA Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 62 MEA Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 63 GCC Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 64 South Africa Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 65 Rest of MEA Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 66 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 AbbVie Inc.: Product Benchmarking
Table 68 AbbVie Inc.: Strategic Outlook
Table 69 AC IMMUNE SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 AC IMMUNE SA: Product Benchmarking
Table 71 AC IMMUNE SA: Strategic Outlook
Table 72 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Biogen: Product Benchmarking
Table 74 Biogen: Strategic Outlook
Table 75 Eisai Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Eisai Inc.: Product Benchmarking
Table 77 Eisai Inc.: Strategic Outlook
Table 78 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 GSK plc: Product Benchmarking
Table 80 GSK plc: Strategic Outlook
Table 81 Grifols, S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Grifols, S.A.: Product Benchmarking
Table 83 Grifols, S.A.: Strategic Outlook
Table 84 Janssen Pharmaceutica NV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Janssen Pharmaceutica NV: Product Benchmarking
Table 86 Janssen Pharmaceutica NV: Strategic Outlook
Table 87 Neurim Pharmaceuticals LTD.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Neurim Pharmaceuticals LTD.: Product Benchmarking
Table 89 Novo Nordisk: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Novo Nordisk: Product Benchmarking
Table 91 Novo Nordisk: Strategic Outlook
Table 92 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 94 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 95 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 97 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Eli Lilly and Company: Product Benchmarking
Table 99 Eli Lilly and Company: Strategic Outlook
Table 100 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Merck & Co., Inc.: Product Benchmarking
Table 102 Merck & Co., Inc.: Strategic Outlook

List of Figures
Figure 1 Alzheimer’s Therapeutics Market Segmentation
Figure 2 Alzheimer’s Therapeutics Market by Drug Class: Market Attractiveness Index
Figure 3 Alzheimer’s Therapeutics Market by Type of Treatment: Market Attractiveness Index
Figure 4 Alzheimer’s Therapeutics Market by Route of Administration: Market Attractiveness Index
Figure 5 Alzheimer’s Therapeutics Market by Distribution Channel: Market Attractiveness Index
Figure 6 Alzheimer’s Therapeutics Market Attractiveness Index by Region
Figure 7 Alzheimer’s Therapeutics Market: Market Dynamics
Figure 8 Alzheimer’s Therapeutics Market: Impact Analysis
Figure 9 Alzheimer’s Therapeutics Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 10 Alzheimer’s Therapeutics Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 11 Alzheimer’s Therapeutics Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 12 Short Term & Long Term Planning
Figure 13 Impact of U.S. and China Trade War
Figure 14 Most Impacted Countries
Figure 15 Alzheimer’s Therapeutics Market: Porter’s Five Forces Analysis
Figure 16 Alzheimer’s Therapeutics Market: PEST Analysis
Figure 17 Alzheimer’s Therapeutics Market Attractiveness Index by Drug Class
Figure 18 Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
Figure 19 Alzheimer’s Therapeutics Market Share Forecast by Drug Class, 2026, 2031, 2036 (%)
Figure 20 Cholinesterase Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 21 Cholinesterase Inhibitors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 22 NMDA Receptor Antagonists Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 23 NMDA Receptor Antagonists Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 24 Combination Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 25 Combination Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 26 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 27 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 28 Alzheimer’s Therapeutics Market Attractiveness Index by Drug Class
Figure 29 Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR %)
Figure 30 Alzheimer’s Therapeutics Market Share Forecast by Type of Treatment, 2026, 2031, 2036 (%)
Figure 31 Symptomatic Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 32 Symptomatic Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 33 Disease-Modifying Therapies (DMTs) Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 34 Disease-Modifying Therapies (DMTs) Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 35 Alzheimer’s Therapeutics Market Attractiveness Index by Route of Administration
Figure 36 Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 37 Alzheimer’s Therapeutics Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
Figure 38 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 39 Oral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 40 Injectable Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 41 Injectable Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 42 Transdermal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 43 Transdermal Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 44 Alzheimer’s Therapeutics Market Attractiveness Index by Distribution Channel
Figure 45 Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 46 Alzheimer’s Therapeutics Market Share Forecast by Distribution Channel, 2026, 2031, 2036 (%)
Figure 47 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 48 Hospital Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 49 Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 50 Retail Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 51 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 52 Online Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 53 Alzheimer’s Therapeutics Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
Figure 54 Alzheimer’s Therapeutics Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 55 Alzheimer’s Therapeutics Market by Region, 2026-2036 (US$ Mn)
Figure 56 North America Alzheimer’s Therapeutics Market Attractiveness Index
Figure 57 North America Alzheimer’s Therapeutics Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 58 North America Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 59 North America Alzheimer’s Therapeutics Market Share Forecast by Country, 2026 & 2036 (%)
Figure 60 North America Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
Figure 61 North America Alzheimer’s Therapeutics Market Share Forecast by Drug Class, 2026 & 2036 (%)
Figure 62 North America Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR %)
Figure 63 North America Alzheimer’s Therapeutics Market Share Forecast by Type of Treatment, 2026 & 2036 (%)
Figure 64 North America Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 65 North America Alzheimer’s Therapeutics Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 66 North America Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 67 North America Alzheimer’s Therapeutics Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 68 U.S. Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 69 Canada Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 70 Europe Alzheimer’s Therapeutics Market Attractiveness Index
Figure 71 Europe Alzheimer’s Therapeutics Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 72 Europe Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 73 Europe Alzheimer’s Therapeutics Market Share Forecast by Country, 2026 & 2036 (%)
Figure 74 Europe Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
Figure 75 Europe Alzheimer’s Therapeutics Market Share Forecast by Drug Class, 2026 & 2036 (%)
Figure 76 Europe Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR %)
Figure 77 Europe Alzheimer’s Therapeutics Market Share Forecast by Type of Treatment, 2026 & 2036 (%)
Figure 78 Europe Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 79 Europe Alzheimer’s Therapeutics Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 80 Europe Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 81 Europe Alzheimer’s Therapeutics Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 82 Germany Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 83 UK Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 84 France Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 85 Italy Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 86 Spain Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 87 Rest of Europe Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 88 Asia Pacific Alzheimer’s Therapeutics Market Attractiveness Index
Figure 89 Asia Pacific Alzheimer’s Therapeutics Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 90 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 91 Asia Pacific Alzheimer’s Therapeutics Market Share Forecast by Country, 2026 & 2036 (%)
Figure 92 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
Figure 93 Asia Pacific Alzheimer’s Therapeutics Market Share Forecast by Drug Class, 2026 & 2036 (%)
Figure 94 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR %)
Figure 95 Asia Pacific Alzheimer’s Therapeutics Market Share Forecast by Type of Treatment, 2026 & 2036 (%)
Figure 96 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 97 Asia Pacific Alzheimer’s Therapeutics Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 98 Asia Pacific Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 99 Asia Pacific Alzheimer’s Therapeutics Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 100 Japan Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 101 China Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 102 India Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 103 Australia Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 104 Rest of Asia Pacific Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 105 Latin America Alzheimer’s Therapeutics Market Attractiveness Index
Figure 106 Latin America Alzheimer’s Therapeutics Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 107 Latin America Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 108 Latin America Alzheimer’s Therapeutics Market Share Forecast by Country, 2026 & 2036 (%)
Figure 109 Latin America Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
Figure 110 Latin America Alzheimer’s Therapeutics Market Share Forecast by Drug Class, 2026 & 2036 (%)
Figure 111 Latin America Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR %)
Figure 112 Latin America Alzheimer’s Therapeutics Market Share Forecast by Type of Treatment, 2026 & 2036 (%)
Figure 113 Latin America Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 114 Latin America Alzheimer’s Therapeutics Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 115 Latin America Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 116 Latin America Alzheimer’s Therapeutics Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 117 Brazil Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 118 Mexico Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 119 Rest of Latin America Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 120 MEA Alzheimer’s Therapeutics Market Attractiveness Index
Figure 121 MEA Alzheimer’s Therapeutics Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 122 MEA Alzheimer’s Therapeutics Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 123 MEA Alzheimer’s Therapeutics Market Share Forecast by Country, 2026 & 2036 (%)
Figure 124 MEA Alzheimer’s Therapeutics Market Forecast by Drug Class, 2026-2036 (US$ Billion, AGR %)
Figure 125 MEA Alzheimer’s Therapeutics Market Share Forecast by Drug Class, 2026 & 2036 (%)
Figure 126 MEA Alzheimer’s Therapeutics Market Forecast by Type of Treatment, 2026-2036 (US$ Billion, AGR %)
Figure 127 MEA Alzheimer’s Therapeutics Market Share Forecast by Type of Treatment, 2026 & 2036 (%)
Figure 128 MEA Alzheimer’s Therapeutics Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 129 MEA Alzheimer’s Therapeutics Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 130 MEA Alzheimer’s Therapeutics Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 131 MEA Alzheimer’s Therapeutics Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 132 GCC Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 133 South Africa Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 134 Rest of MEA Alzheimer’s Therapeutics Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 135 AbbVie Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 136 AbbVie Inc.: R&D, 2020-2024 (US$ Million, AGR %)
Figure 137 AbbVie Inc.: Regional Market Shares (%), 2024
Figure 138 AbbVie Inc.: Business Segment Market Shares (%), 2024
Figure 139 AC IMMUNE SA: Net Revenue, 2022-2024 (US$ Million, AGR %)
Figure 140 AC IMMUNE SA: R&D, 2020-2024 (US$ Million, AGR %)
Figure 141 Biogen: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 142 Biogen: R&D, 2020-2024 (US$ Million, AGR %)
Figure 143 Biogen: Regional Market Shares (%), 2024
Figure 144 Eisai Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 145 Eisai Inc.: R&D, 2020-2024 (US$ Million, AGR %)
Figure 146 Eisai Inc.: Regional Market Shares (%), 2024
Figure 147 GSK plc: Net Revenue, 2020-20234(US$ Million, AGR %)
Figure 148 GSK plc: R&D, 2020-2024 (US$ Million, AGR %)
Figure 149 GSK plc: Regional Market Shares (%), 2024
Figure 150 GSK plc: Business Segment Market Shares (%), 2024
Figure 151 Grifols, S.A.: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 152 Grifols, S.A.: R&D, 2020-2024 (US$ Million, AGR %)
Figure 153 Grifols, S.A.: Regional Market Shares (%), 2024
Figure 154 Grifols, S.A.: Business Segment Market Shares (%), 2024
Figure 155 Janssen Pharmaceutica NV: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 156 Janssen Pharmaceutica NV: R&D, 2020-2024 (US$ Million, AGR %)
Figure 157 Janssen Pharmaceutica NV: Regional Market Shares (%), 2024
Figure 158 Janssen Pharmaceutica NV: Business Segment Market Shares (%), 2024
Figure 159 Novo Nordisk: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 160 Novo Nordisk: R&D, 2020-2024 (US$ Million, AGR %)
Figure 161 Novo Nordisk: Regional Market Shares (%), 2024
Figure 162 Novo Nordisk: Business Segment Market Shares (%), 2024
Figure 163 F. Hoffmann-La Roche Ltd: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 164 F. Hoffmann-La Roche Ltd: R&D, 2020-2024 (US$ Million, AGR %)
Figure 165 F. Hoffmann-La Roche Ltd: Business Segment Market Shares (%), 2024
Figure 166 Takeda Pharmaceutical Company Limited: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 167 Takeda Pharmaceutical Company Limited: R&D, 2020-2024 (US$ Million, AGR %)
Figure 168 Takeda Pharmaceutical Company Limited: Regional Market Shares (%), 2024
Figure 169 Eli Lilly and Company: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 170 Eli Lilly and Company: R&D, 2020-2024 (US$ Million, AGR %)
Figure 171 Eli Lilly and Company: Regional Market Shares (%), 2024
Figure 172 Eli Lilly and Company: Business Segment Market Shares (%), 2024
Figure 173 Merck & Co., Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 174 Merck & Co., Inc.: R&D, 2020-2024 (US$ Million, AGR %)
Figure 175 Merck & Co., Inc.: Regional Market Shares (%), 2024
Figure 176 Merck & Co., Inc.: Business Segment Market Shares (%), 2024

List of Companies Profiled in the Report
AbbVie Inc.
AC IMMUNE SA
Biogen
Eisai Inc.
GSK plc
Grifols, S.A.
Janssen Pharmaceutica NV
Neurim Pharmaceuticals LTD.
Novo Nordisk
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Merck & Co., Inc.

List of Other Companies Mentioned in the Report
Aliada Therapeutics
C2N Diagnostics LLC
GE HealthCare
Grifols S.A.
Illimis Therapeutics
Luye Pharma
Pfizer
Sanofi

List of Associations Mentioned in the Report
Alzheimer’s Association (AA)
Alzheimer’s Disease International (ADI)
Alzheimer’s Drug Discovery Foundation (ADDF)
Alzheimer Europe (AE)
American Academy of Neurology (AAN)
American Neurological Association (ANA)
British Neuroscience Association (BNA)
European Academy of Neurology (EAN)
European Brain Council (EBC)
International Alzheimer’s and Related Dementias Society (IADRS)
International Society to Advance Alzheimer’s Research and Treatment (ISTAART)
National Institute on Aging (NIA)
Society for Neuroscience (SfN)
World Dementia Council (WDC)
World Health Organization – Dementia Programme (WHO)